Repression of endothelial TLR3 is a potential mechanism of SARS-CoV-2 infection-associated lung vascular remodeling

NewsGuard 100/100 Score

In a recent study posted to the bioRxiv* preprint server, researchers investigated whether endothelial TLR3 (toll-like receptor 3) insufficiency contributes to lung vascular remodeling induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Study: A role for Toll-like receptor 3 in lung vascular remodeling associated with SARS-CoV-2 infection. Image Credit: Dotted Yeti/Shutterstock
Study: A role for Toll-like receptor 3 in lung vascular remodeling associated with SARS-CoV-2 infection. Image Credit: Dotted Yeti/Shutterstock

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Background

The coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented morbidity and mortality across the globe. The continual emergence of SARS-CoV-2 variants with greater infectivity, transmissibility, and immune evasiveness has threatened the efficacy of COVID-19 vaccines and therapeutic agents such as monoclonal antibodies, warranting the development of more effective treatment options.

Studies have reported cardiac complications among patients with coronavirus disease 2019 (COVID-19) and post-acute COVID-19 or long COVID. Endothelial cell (EC) dysfunction and pulmonary vasculature remodeling, including thickening of the pulmonary arterial wall, pulmonary hypertension (PH), ventricular remodeling, and heterogeneous lung perfusion, have been reported among SARS-CoV-2-infected individuals.

TLR3 is a critical component of antiviral responses since it detects viral endosomal ribonucleic acid (RNA) and enhances type I IFN (interferon) expression. An improved understanding of the cardiovascular effects of COVID-19 and exploration of underlying mechanisms can aid in developing targeted and more effective therapies to reduce the health burden of COVID-19.

About the study

The present study investigated whether COVID-19 potentiates pulmonary microvascular and arterial remodeling with endothelial cell apoptosis through lowered toll-like receptor 3 expression.

PAECs (pulmonary artery endothelial cells) and HLMVECs (human lung microvascular endothelial cells) were obtained for cell culture experiments, following which SARS-CoV-2 RNA was isolated and subjected to real-time quantitative polymerase chain reaction (PCR) analysis. In addition, pulmonary samples from obtained from COVID-19 SARS-CoV-2-positive individuals’ explanted lungs.

β-actin, SARS-CoV-2 nucleocapsid (N) protein, toll-like receptor 3 antibodies, and SARS-CoV-2 strains such as USA-WA1/2020, and mice-adapted MA10, were used for serological assessments. Mesocricetus auratus (Syrian hamsters), wild-type (101045 strain) mice and TLR3-/- murine animals (005217 strain) were used for the animal experiments. The murine animals were challenged with SARS-CoV-2 intranasally, and a few of them were administered either intraperitoneal injections of 10.0 mg per kg Poly(I:C) thrice weekly, or mock (control) injections of phosphate-buffered saline (PBS).

Any changes in the murine body weight were assessed. After a week of treatment, mice underwent echocardiography analysis, following which murine blood was collected, and their cardiac and pulmonary tissues were harvested. Hamster tissues obtained were subjected to protein isolation and immunoblotting analyses. In addition, histological examination and immunohistochemistry (IHC) analysis were performed.

Results

In the pulmonary tissues of individuals and Syrian hamsters infected by SARS-CoV-2, the team observed thickening of pulmonary arterial media, microvascular rarefaction, and reduced microvascular density (MVD), consistent with alveolar tissue architectural disruption. SARS-CoV-2 infections induced pulmonary arterial and microvasculature remodeling, endothelial cell apoptosis, and increased arterial muscularization in lungs, and in situ among PAECs, with lowered TLR3 expression.

The team detected SARS-CoV-2 N, spike (S), and envelope (E) protein messenger RNA (mRNA) six hours post-infection. COVID-19 increased the cross-sectional area (CSA) among RV (right ventricular) cardiomyocytes in the infected hamsters. Post-SARS-CoV-2 MA10 infection, toll-like receptor 3 knockout murine animals showed increased remodeling in the pulmonary arteries and apoptosis in the endothelial cells.

Injections of polyinosinic:polycytidylic acid [poly(I:C)], an agonist of toll-like receptor 3, prevented the loss of microvascular density and decreased tissue injury, blood vessel remodeling, inflammation, and endothelial cell apoptosis in the pulmonary tissues of SARS-CoV-2 MA10-infected animals. Furthermore, lowered PAT (pulmonary arterial acceleration time) versus PET (pulmonary ejection time), and increased PAP (pulmonary arterial pressure) were noted among SARS-CoV-2 MA10- infected TLR3+/+ murine animals, which were prevented by Poly(I:C) therapy.

Moreover, left ventricular (LV) ejection fraction (EF) was lowered among TLR3-/- mice post-COVID-19, but not among TLR3+/+ SARS-CoV-2-infected mice, indicative of the cardiovascular protection conferred by toll-like receptor 3 during SARS-CoV-2 infections. Poly(I:C) elevated the levels of chemokines and cytokines such as interleukin-6, interleukin-1b, interleukin-10, tumor necrosis factor-alpha (TNF-α), and C-X-C motif ligand 10 (CXCL-10). The findings indicated that Poly(I:C) induced protective immunological responses. TLR-/- murine animals showed lower expression of the cytokines following SARS-CoV-2 MA10 infections.

Conclusion

Overall, the study findings showed that SARS-CoV-2 infection induces pulmonary microvascular and macrovascular remodeling and endothelial cell apoptosis with lowered toll-like receptor 3 expression. Therefore, the enhancement of TLR3 levels could be considered a probable therapeutic strategy against SARS-CoV-2. The findings indicated that toll-like receptor 3 agonists protect the heart and the lung post-COVID-19, and therefore, TLR-3 agonists could widen the therapeutic landscape of COVID-19.

*Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Pooja Toshniwal Paharia

Written by

Pooja Toshniwal Paharia

Dr. based clinical-radiological diagnosis and management of oral lesions and conditions and associated maxillofacial disorders.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Toshniwal Paharia, Pooja Toshniwal Paharia. (2023, January 30). Repression of endothelial TLR3 is a potential mechanism of SARS-CoV-2 infection-associated lung vascular remodeling. News-Medical. Retrieved on May 18, 2024 from https://www.news-medical.net/news/20230130/Repression-of-endothelial-TLR3-is-a-potential-mechanism-of-SARS-CoV-2-infection-associated-lung-vascular-remodeling.aspx.

  • MLA

    Toshniwal Paharia, Pooja Toshniwal Paharia. "Repression of endothelial TLR3 is a potential mechanism of SARS-CoV-2 infection-associated lung vascular remodeling". News-Medical. 18 May 2024. <https://www.news-medical.net/news/20230130/Repression-of-endothelial-TLR3-is-a-potential-mechanism-of-SARS-CoV-2-infection-associated-lung-vascular-remodeling.aspx>.

  • Chicago

    Toshniwal Paharia, Pooja Toshniwal Paharia. "Repression of endothelial TLR3 is a potential mechanism of SARS-CoV-2 infection-associated lung vascular remodeling". News-Medical. https://www.news-medical.net/news/20230130/Repression-of-endothelial-TLR3-is-a-potential-mechanism-of-SARS-CoV-2-infection-associated-lung-vascular-remodeling.aspx. (accessed May 18, 2024).

  • Harvard

    Toshniwal Paharia, Pooja Toshniwal Paharia. 2023. Repression of endothelial TLR3 is a potential mechanism of SARS-CoV-2 infection-associated lung vascular remodeling. News-Medical, viewed 18 May 2024, https://www.news-medical.net/news/20230130/Repression-of-endothelial-TLR3-is-a-potential-mechanism-of-SARS-CoV-2-infection-associated-lung-vascular-remodeling.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Long-term impact of COVID-19 on body composition explored